Study Summary
This is an open label, phase I study to assess the safety and efficacy of CLL1 CAR-T in patients with relapsed and refractory acute myeloid leukemia
Interested in this trial?
Submit an InquiryInterventions
CLL1 CAR-TDRUG
A single infusion of autologous CLL1 CAR-T cells administered intravenously
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital, Zhejiang University | Hangzhou | China |